SAB Biotherapeutics (SABS) versus Its Peers Head-To-Head Review

SAB Biotherapeutics (NASDAQ:SABS) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare SAB Biotherapeutics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of recent recommendations for SAB Biotherapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0	0	5	0	3.00
SAB Biotherapeutics Competitors	1973	5464	14072	305	2.58

SAB Biotherapeutics presently has a consensus target price of $11.40, indicating a potential upside of 570.59%. As a group, “Biological products, except diagnostic” companies have a potential upside of 115.24%. Given SAB Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than its peers.

Risk & Volatility

SAB Biotherapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics’ peers have a beta of -4.48, suggesting that their average stock price is 548% less volatile than the S&P 500.

Insider & Institutional Ownership

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 15.6% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares SAB Biotherapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SAB Biotherapeutics	$2.24 million	-$42.19 million	-0.46
SAB Biotherapeutics Competitors	$575.17 million	-$70.96 million	-1.94

SAB Biotherapeutics’ peers have higher revenue, but lower earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares SAB Biotherapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
SAB Biotherapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Summary

SAB Biotherapeutics beats its peers on 9 of the 13 factors compared.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.